New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its ...

Thomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most ...

Roche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped ...

Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an ...

Novartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the ...

Every Friday, The Leadership Edit looks at the people taking new roles across European biotech and what their moves may tell us about the companies they join. We’ll follow chief executives, scientific ...

PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company’s global commercial strategy and further strengthening its commercial ...

Roche signed two research partnerships on Sept. 24: one with Atavistik Bio to discover drugs for cardiovascular, renal and metabolic diseases, and another with Earendil Labs to develop cancer ...

GSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager for multiple myeloma from ...

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies.

London-based Basecamp Research has raised $140 million (€122 million) in an oversubscribed Series C to expand its biological AI models and move a preclinical therapeutics pipeline toward the clinic.

Warsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC. The round follows a €9m seed ...